Summary

• INVEGA TRINZA has not been systematically studied in patients with renal impairment.¹
• Paliperidone is substantially excreted unchanged by the kidney (59%) and clearance is decreased in patients with renal impairment, who should be given reduced doses.^2,3
• For patients with mild renal impairment (creatinine clearance [CrCl] ≥50 mL/min to <80 mL/min), initiate paliperidone palmitate 1-month at lower dose, then transition to INVEGA TRINZA as directed by the local labeling.³
• INVEGA TRINZA is not recommended in patients with moderate or severe renal impairment (CrCl <50 mL/min).³

PHARMACOKINETICS

No specific pharmacokinetic studies have been performed with INVEGA TRINZA in patients with renal impairment. The existing information is obtained from studies with oral paliperidone or is based on the population pharmacokinetic modelling of oral paliperidone and INVEGA TRINZA.¹

LITERATURE SEARCH

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT Drug File (and/or other resources, including internal/external databases) conducted through 12 April 2024 did not identify any relevant citations pertaining to this topic.